Daniel Molin
@drdanielmolin.bsky.social
Lymphoma doctor in Uppsala, Sweden.
Chair of the Swedish lymphoma group and the Swedish Hodgkin lymphoma group.
Chair of the Swedish lymphoma group and the Swedish Hodgkin lymphoma group.
Read about my view on late side effects after modern radiotherapy for Hodgkin lymphoma. Much progress since the days of mantle therapy. Don’t abandon radiotherapy at the cost of more relapses.
medicaljournalssweden.se/actaoncologi...
medicaljournalssweden.se/actaoncologi...
View of Improved therapies, incomplete data: late toxicity after modern classical Hodgkin Lymphoma radiotherapy
medicaljournalssweden.se
November 13, 2025 at 2:56 PM
Read about my view on late side effects after modern radiotherapy for Hodgkin lymphoma. Much progress since the days of mantle therapy. Don’t abandon radiotherapy at the cost of more relapses.
medicaljournalssweden.se/actaoncologi...
medicaljournalssweden.se/actaoncologi...
HD21, BrECADD for Hodgkin patients >60 years. PFS 91.5% at 2 years. We use mostly N-AVD for these patients but BrECADD can be an effective alternative for fit patients, with shorter treatment duration and less doxorubicine.
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Pros...
PURPOSEPositron emission tomography (PET)-guided therapy with 4-6 cycles of brentuximab vedotin,
etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD)
is highly effective ...
ascopubs.org
July 25, 2025 at 2:38 PM
HD21, BrECADD for Hodgkin patients >60 years. PFS 91.5% at 2 years. We use mostly N-AVD for these patients but BrECADD can be an effective alternative for fit patients, with shorter treatment duration and less doxorubicine.
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Fertility data from HD21, just published. Compared with eBEACOPP, BrECADD led to better gonadal recovery and higher parenthood rates. Support BrECADD as preferred first-line treatment for younger pts with advanced Hodgkin lymphoma.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) has shown higher efficacy and better acute tol…
www.sciencedirect.com
July 11, 2025 at 7:16 AM
Fertility data from HD21, just published. Compared with eBEACOPP, BrECADD led to better gonadal recovery and higher parenthood rates. Support BrECADD as preferred first-line treatment for younger pts with advanced Hodgkin lymphoma.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Reposted by Daniel Molin
6x Nivo-AVD with PFS & OS benefit and better tolerability vs 6x BV-AVD in AS-HL pts ≥60 years in the randomised S1826 trial. Efficacy driven by EBV status? PRO-CTCAE confirming better tolerability & revealing discrepancy to physician reporting @ascocancer.bsky.social ascopubs.org/doi/10.1200/...
June 17, 2025 at 8:56 AM
6x Nivo-AVD with PFS & OS benefit and better tolerability vs 6x BV-AVD in AS-HL pts ≥60 years in the randomised S1826 trial. Efficacy driven by EBV status? PRO-CTCAE confirming better tolerability & revealing discrepancy to physician reporting @ascocancer.bsky.social ascopubs.org/doi/10.1200/...
The Swedish lymphoma group’s annual conference. Always a pleasure.
May 16, 2025 at 3:46 PM
The Swedish lymphoma group’s annual conference. Always a pleasure.
Here we introduce a simple 3-point frailty score for older Hodgkin patients to inform clinical decisions and prospective trials. Published today!
haematologica.org/haematologic...
haematologica.org/haematologic...
Early View
| Haematologica
haematologica.org
April 24, 2025 at 4:11 PM
Here we introduce a simple 3-point frailty score for older Hodgkin patients to inform clinical decisions and prospective trials. Published today!
haematologica.org/haematologic...
haematologica.org/haematologic...
Speaker at the annual course in lymphatic malignancies, together with lymphoma experts from many parts of Sweden.
April 11, 2025 at 6:39 AM
Speaker at the annual course in lymphatic malignancies, together with lymphoma experts from many parts of Sweden.
Meeting with the Swedish Hodgkin lymphoma group. Always a pleasure!
March 29, 2025 at 12:34 PM
Meeting with the Swedish Hodgkin lymphoma group. Always a pleasure!
Brentuximab Vedin for older frail patients with Hodgkin lymphoma. One of the arms of the BVB-trial now published. A fruitful collaboration between the Nordic lymphoma group and the German Hodgkin study group.
onlinelibrary.wiley.com/share/XSFFTV...
onlinelibrary.wiley.com/share/XSFFTV...
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial
You have to enable JavaScript in your browser's settings in order to use the eReader.
onlinelibrary.wiley.com
March 24, 2025 at 3:23 PM
Brentuximab Vedin for older frail patients with Hodgkin lymphoma. One of the arms of the BVB-trial now published. A fruitful collaboration between the Nordic lymphoma group and the German Hodgkin study group.
onlinelibrary.wiley.com/share/XSFFTV...
onlinelibrary.wiley.com/share/XSFFTV...
Reposted by Daniel Molin
A woman with multiply relapsed multiple myeloma had complete remission with cilta-cel, but a low-grade T-cell lymphoma soon developed in the GI tract that contained an insertion of the CAR construct disrupting expression of p53. Read the Brief Report: nej.md/40Yq3gO
#MedSky #Oncology
#MedSky #Oncology
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...
nej.md
February 7, 2025 at 6:13 PM
A woman with multiply relapsed multiple myeloma had complete remission with cilta-cel, but a low-grade T-cell lymphoma soon developed in the GI tract that contained an insertion of the CAR construct disrupting expression of p53. Read the Brief Report: nej.md/40Yq3gO
#MedSky #Oncology
#MedSky #Oncology
Reposted by Daniel Molin
HLH, a cytokine-mediated hyperinflammation syndrome, causes fever, pancytopenia, and hemophagocytosis and is often fatal. Antiinflammatory agents, etoposide, and interferon-γ antibody are the main treatments. Learn more in a new review: nej.md/40Jps19
#MedSky #Oncology
#MedSky #Oncology
Hemophagocytic Lymphohistiocytosis | NEJM
HLH, a cytokine-mediated hyperinflammation syndrome, causes fever, pancytopenia, and
hemophagocytosis and is often fatal. Antiinflammatory agents, etoposide, and interferon-γ
antibody are the main ...
nej.md
February 8, 2025 at 1:38 PM
HLH, a cytokine-mediated hyperinflammation syndrome, causes fever, pancytopenia, and hemophagocytosis and is often fatal. Antiinflammatory agents, etoposide, and interferon-γ antibody are the main treatments. Learn more in a new review: nej.md/40Jps19
#MedSky #Oncology
#MedSky #Oncology
Speaking at the UK Hodgkin lymphoma forum. Excellent meeting. Thank you for the nice invitation Graham Collins and colleagues!
February 4, 2025 at 1:35 PM
Speaking at the UK Hodgkin lymphoma forum. Excellent meeting. Thank you for the nice invitation Graham Collins and colleagues!